title: Circulating interleukin-2 receptors are a group of multimeric proteins with immunoreactivity for interleukin-2 receptor alpha, beta, and gamma chains.
abstract: Soluble interleukin-2 receptor (sIL-2R) alpha chain serum levels as determined by enzyme-linked immunosorbant assay (ELISA) are commonly used to monitor various inflammatory and neoplastic disorders associated with lymphocytic proliferation and activation. The in vivo structure of this soluble receptor species, however, is not characterized. We investigated sera with elevated sIL-2R serum levels of patients with histologically proven cutaneous T cell lymphoma (CTCL) and high-dose IL-2-treated melanoma patients and healthy donors. Purified recombinant IL-2R alpha and beta chain molecules, produced by transfection of NIH/3T3 fibroblasts and CHO cells, served as positive controls for purification and detection procedures. For selective enrichment of IL-2R molecules from supernatants and sera, affinity columns were prepared by coupling recombinant IL-2 or monoclonal antibodies against the alpha and the beta chain of the IL-2R complex to cyanogen bromide-activated Sepharose. Western blotting with affinity-purified fractions under reducing and nonreducing conditions revealed proteins that showed immunoreactivity for IL-2R alpha, beta, and gamma chain using several detection antibodies against these molecules. We conclude that the composition of sIL-2R in vivo is more complex than that of recombinant sIL-2R and can include all three IL-2R chains.
authors.affiliation: Department of Dermatology, University of Zurich Medical School, Gloriastrasse 31, CH 8091 Zurich, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Dummer
authors.forename: G
authors.initials: G
authors.lastname: Posseckert
authors.forename: K
authors.initials: K
authors.lastname: Sugamura
authors.forename: H
authors.initials: H
authors.lastname: Grundmann
authors.forename: G
authors.initials: G
authors.lastname: Burg
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015153:Blotting, Western; D016022:Case-Control Studies; D002846:Chromatography, Affinity; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000097:blood*; D008545:Melanoma / Q000097:blood / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012878:Skin Neoplasms / Q000097:blood*; D012995:Solubility
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2; D015375:Receptors, Interleukin-2